High clinical and morphologic response using 90Y-DOTA-octreotate sequenced with 177Lu-DOTA-octreotate induction peptide receptor chemoradionuclide therapy (PRCRT) for bulky neuroendocrine tumours
暂无分享,去创建一个
T. Akhurst | R. Hicks | M. Michael | M. Hofman | G. Kong | P. Eu | J. Callahan | D. Pattison